Low-Dose tamoxifen may shield radiation survivors from breast cancer
NCT ID NCT01196936
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase IIB trial tests whether a low dose of tamoxifen (a hormone-blocking drug) can reduce breast cancer risk in people who received chest radiation therapy before age 40. The study involves 84 survivors and measures changes in breast density as a risk indicator. If successful, it could lead to a simple prevention strategy for this high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tamoxifen citrate (low-dose)
What this could lead to
If it works, this could offer a way to lower breast cancer risk for people who had chest radiation as children or young adults.
What could go wrong
This is a small, early-phase trial (84 people) testing a surrogate marker (breast density), not cancer itself. Results may not confirm real risk reduction, and tamoxifen can cause side effects like hot flashes and blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
University Health Network, Toronto
Toronto, Ontario, M5G 2M9, Canada
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Colorado, Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
University of Michigan
Ann Arbor, Michigan, 48109-5718, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Wake Forest University
Winston-Salem, North Carolina, 27157, United States